Catalyst Pharmaceuticals (CPRX) Operating Income (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Operating Income came in at $73.2 million in Q1 2026, up 15.57% YoY from $63.4 million in Q1 2025, and up 18.41% on a QoQ basis from $61.8 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Operating Income (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Operating Income data on file, last reported at $73.2 million in Q1 2026.
- Quarterly Operating Income rose 15.57% year-over-year to $73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $267.6 million (up 15.68% YoY) and the FY2025 annual result came in at $257.8 million, up 32.11% from the prior year.
- Operating Income climbed to $73.2 million in Q1 2026, from $61.8 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $73.2 million in Q1 2026 to a low of -$37.2 million in Q3 2023.
- A 5-year average of $42.0 million and a median of $46.7 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income slumped 248.15% — and 2024, when it jumped 236.9%.
- Tracing CPRX's Operating Income over 5 years: stood at $30.8 million in 2022, then surged by 35.36% to $41.7 million in 2023, then soared by 50.73% to $62.8 million in 2024, then retreated by 1.59% to $61.8 million in 2025, then grew by 18.41% to $73.2 million in 2026.
- The last three Operating Income figures came in at $73.2 million (Q1 2026), $61.8 million (Q4 2025), and $66.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 73.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.23 Mn |
| Dec 31, 2025 | 61.85 Mn |
| Sep 30, 2025 | 66.27 Mn |
| Jun 30, 2025 | 66.30 Mn |
| Mar 31, 2025 | 63.37 Mn |
| Dec 31, 2024 | 62.84 Mn |
| Sep 30, 2024 | 50.91 Mn |
| Jun 30, 2024 | 54.25 Mn |
| Mar 31, 2024 | 27.13 Mn |
| Dec 31, 2023 | 41.69 Mn |
| Sep 30, 2023 | -37.19 Mn |
| Jun 30, 2023 | 46.70 Mn |
| Mar 31, 2023 | 35.61 Mn |
| Dec 31, 2022 | 30.80 Mn |
| Sep 30, 2022 | 25.10 Mn |
| Jun 30, 2022 | 28.57 Mn |
| Mar 31, 2022 | 17.37 Mn |
| Dec 31, 2021 | 12.74 Mn |
| Sep 30, 2021 | 14.00 Mn |
| Jun 30, 2021 | 15.84 Mn |